Akoya Biosciences, Inc.
Doing business as Phenoptics Part of Quanterix Corporation
- UEI
- NHN4QEBQTJT3
- CAGE
- 7NJQ4
- Primary NAICS
- 334516 Analytical Laboratory Instrument Manufacturing
- SAM.gov registration
- Expired
Company facts
- FY2025 rankings
-
Its parent company, Quanterix Corporation, ranks #85 in PSC 6550
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
Billerica, MA
FMFEHF5ACEV2
-
Parent
Billerica, MA
FMFEHF5ACEV2
- SAM.gov registration date
- Website
- quanterix.com
- Founded
- 2007
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $54,329 |
| FY2025 | $224,530 |
| FY2024 | $226,355 |
| FY2023 | $479,442 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $54,329 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Similar vendors
About the company
Akoya Biosciences, Inc., doing business as Phenoptics, manufactures spatial phenotyping and advanced tissue imaging systems, reagents, and consumables for federal biomedical research and clinical diagnostics as a prime contractor operating under full-and-open competition with no set-aside designation. The company is a self-certified small disadvantaged business and subsidiary of Quanterix Corporation, headquartered in Billerica, Massachusetts, with manufacturing and fulfillment operations based in Marlborough, Massachusetts.
Akoya's federal footprint centers on equipment, maintenance services, and consumable supplies for medical imaging platforms. Representative work includes a $470,560 purchase order from the National Cancer Institute for multiplexed immunofluorescence and quantitative pathology analysis of human central nervous system tumor samples under the Spatial Tissue Exploration Program; a $195,720 five-year preventive maintenance contract with NCI for an Akoya PhenoImager HT instrument running through June 2029; a $379,590 sole-source award from Veterans Integrated Service Network 1 for an Akoya Slide Scanner; and a $225,725 single-award Indefinite Delivery Vehicle with VA VISN 1 for OPAL reagent packs, under which the VA has issued six delivery orders totaling approximately $125,192 through March 2026. The company also delivers PhenoCycler antibodies, PhenoImager and PhenoImager Gold servicing, Mantra imaging system maintenance, PhenoCycler reagents and preventive maintenance, and software upgrades and maintenance across both customer sets.
Customer concentration is split between two federal healthcare and research entities. The Department of Veterans Affairs Veterans Integrated Service Network 1 anchors 23 awards valued at $1.9 million combined potential value, while the National Cancer Institute accounts for 29 awards valued at $1.2 million. Three additional NIH institutes—the National Institute of Allergy and Infectious Diseases, the National Institute of Dental and Craniofacial Research, and VA VISN 21—round out the active portfolio. The concentration reflects Akoya's focus on government research and clinical facilities operating its specialized imaging equipment; VA VISN 1 dominates both award count and dollar value, while NCI's higher award count carries lower per-order values reflective of more frequent consumables procurement.
Akoya operates three named parent vehicles: an Indefinite Delivery Contract generating six task orders valued at $139 thousand, and two Blanket Purchase Agreements each generating single task orders. The vehicle portfolio is narrow and customer-specific rather than government-wide, reflecting sole-source positioning on VA and NCI contracts where Akoya equipment is already deployed.
Recent activity has grown modestly—six awards in 2022 and 2023 to ten in 2024—with two awards in 2026 year-to-date as of August 1. Four awards totaling $199 thousand in combined potential value face ultimate completion within the next twenty-four months, creating near-term recompete exposure concentrated in maintenance and reagent supply contracts. The company operates exclusively as a prime contractor with no subcontract footprint in the federal space. Work is primarily performance-based at customer research and medical facilities—the National Cancer Institute in Bethesda, Maryland, and VA medical centers in Vermont and Massachusetts—with administrative and manufacturing operations in Marlborough, Massachusetts.
Quick answers
Is Akoya Biosciences, Inc. registered in SAM.gov?
Akoya Biosciences, Inc.'s SAM.gov registration expired on September 5, 2026.
How much has Akoya Biosciences, Inc. received in federal contracts?
Federal contracts obligated $224,530 to Akoya Biosciences, Inc. in fiscal year 2025 and $984,656 in fiscal years 2023 through 2027.
How does Akoya Biosciences, Inc. rank among federal contractors?
Akoya Biosciences, Inc.'s parent company, Quanterix Corporation, ranked #85 in PSC 6550 in FY2025.
What is Akoya Biosciences, Inc.'s most recent federal award?
Akoya Biosciences, Inc.'s most recent federal contract award is Opal reagent packs (36C24126N0782), from Veterans Integrated Service Network 1 (VHA), on August 1, 2026.
On GovTribe
See Akoya Biosciences, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors